Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Clinical research trials and PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma. PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma clinical trial. Participants oftentimes recieve the finest healthcare available for their PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.

Home > "P" Clinical Trials Conditions > PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma

PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma



PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma

For Condition: Stage 4 Melanoma,stage 3 melanoma,Recurrent Melanoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma.
Details: OBJECTIVES: I. Evaluate the sensitivity, specificity, and accuracy of fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging in detecting metastatic disease in patients with stage III or IV melanoma considered for operative management based on the currently accepted diagnostic work up including CT imaging. II. Determine how often the clinical management of these patients is altered based on FDG PET imaging findings in addition to CT scan results. PROTOCOL OUTLINE: Patients are required to fast for a minimum of 6 hours prior to positron emission tomography (PET) imaging. Fludeoxyglucose F 18 (FDG) is administered IV over 15 minutes followed 50-60 minutes later by whole body PET imaging. Iodinated contrast dye is administered by IV injection and by mouth followed by CT imaging of the chest, abdomen, and pelvis within 2 weeks of PET imaging. Whole body FDG PET imaging and CT imaging of the chest, abdomen, and pelvis are repeated at 6 months. Initial positive PET or CT imaging results are verified based on surgical and/or biopsy findings or clinical follow-up. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 2.5 years.
Eligibility:
Study Type:  Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven melanoma considered for operative management with 1 of the following: Deep primary melanoma (greater than 4 mm, stage IIIA); Regional nodal disease (stage IIIB); Locally or regionally recurrent disease of an extremity considered for operative resection or isolated limb perfusion with curative intent Systemic disease considered for curative resection (stage IV) --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: 18 and over - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Other: Not pregnant or nursing; Fertile patients must use effective contraception; Able to fast for 6 hours; Able to lie still for positron emission tomography imaging; No second malignancy except previously treated nonmelanomatous skin cancer or carcinoma in situ of the cervix; No active infection; No inflammatory disease (sarcoidosis or rheumatoid arthritis); No allergy to shellfish or contrast dye used for CT imaging
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
MaryBrady,  Study Chair,  Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center
New York City,  New York,  10021
United States
 


Additional Information:
Study ID Numbers:  CDR0000067385;  MSKCC-99004,NCI-G99-1619
Study Start Date: February 1999
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004152

Other Stage 3 Melanoma Studies:
1. Gene Therapy in Treating Patients With Metastatic Melanoma

2. Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

3. BMS-247550 in Treating Patients With Stage IV Melanoma

4. Imatinib Mesylate in Treating Patients With Metastatic Melanoma

5. Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Related Studies:

Other stage 3 melanoma Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
Modify your Search

  Other stage 3 melanoma Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103